Record 26 Abstracts at TCT 2026 Adds to More than 20 Years of Data Demonstrating the Safety, Efficacy and Cost Effectiveness of Impella Heart Pumps

DANVERS, Mass. - Oct. 29, 2026 - Johnson & Johnson announces a record 26 presentations featuring the clinical science of Impella™ heart pumps will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 conference, taking place Oct. 31-Nov. 3 in San Diego. The breadth of research reflects the company's continued leadership in generating rigorous clinical evidence to advance the science of heart recovery and improve outcomes for patients facing complex and life-threatening cardiovascular conditions.

Johnson & Johnson MedTech's robust body of clinical evidence in heart recovery spans more than two decades, including randomized controlled trials (RCTs), prospective studies, registries and real-world clinical practice. More than 50,000 Impella patients have been studied, and more than 450,000 patients worldwide have been treated with Impella. This evidence base includes approximately 2,700 peer-reviewed publications and has contributed to the recognition of temporary mechanical circulatory support with Impella in 18 clinical guidelines and consensus statements.

Impella clinical data being presented at TCT builds on that scientific foundation and includes new research from centers around the world across high-risk percutaneous coronary intervention (HRPCI), cardiogenic shock, myocardial recovery, renal perfusion, physiologic risk and next-generation technology. Among the presentations are three analyses of contemporary U.S. and European experience with Impella-supported HRPCI that provide important clinical context in contrast to the CHIP-BCIS3 study results.

"Scientific leadership requires sustained investment, rigorous evaluation of high-quality data, and a willingness to continually improve how we care for patients," said Navin Kapur, M.D., chief medical and scientific officer, Heart Recovery, MedTech, Johnson & Johnson. "The record 26 Impella abstracts at TCT reflect our commitment to partnering with the clinical community to generate the evidence needed to advance understanding, inform best practices and help physicians deliver better outcomes for patients worldwide."

In addition, a novel health-economic model projecting lower lifetime healthcare costs and greater quality-adjusted survival with Impella compared with Intra-Aortic Balloon Pump in heart failure patients undergoing HRPCI will be presented.

• TCT 391: HRPCI in Heart Failure: The Impact of Left Ventricular Unloading on Cost Effectiveness - a Markov Model. (M. Kodenchery, MD, Nov. 1, 2 p.m. PST, station 6)

Impella Events at TCT 2026

Johnson & Johnson MedTech will bring together the clinical community for two events designed to share best practices and promote scientific discussion about the 20 years of clinical evidence supporting the use of Impella across its multiple indications.

• Sunday, Nov. 1, from 6-7:30 p.m. PST. The evening program, featuring Devi Govender, worldwide president, and Navin Kapur, M.D., chief medical and scientific officer, Heart Recovery, MedTech, Johnson & Johnson, will bring together colleagues and leading investigators for an evening of scientific dialogue and discussion around the latest developments in Heart Recovery.
• Johnson & Johnson will also host the World Connect Symposium, Leading in Heart Recovery: Lessons Learned from the Clinical and Scientific Experience with Impella, on Monday, Nov. 2, from 7:45-8:45 a.m. PST at the World Connect Theater, upper level, San Diego Convention & Exhibition Center. The program will bring together leading experts on AMI cardiogenic shock and HRPCI to discuss emerging science and evidence and the future of heart recovery.
• Attendees can also visit Johnson & Johnson MedTech at Booth #4037 to explore Impella technology and connect with members of the heart recovery team.

Innovation and Scientific Evidence

At TCT, attendees will learn about the continued evolution of Impella technology, including prospective evidence from the Impella ECP pivotal trial and continuing access protocol evaluating lower-profile mechanical circulatory support during HRPCI. The scientific program will also feature emerging research intended to deepen understanding of myocardial recovery, renal perfusion and physiologic risk.

Details on key Impella presentations are below:

• TCT 197: Protected PCI with Microaxial-Flow Pump Support: Real-World Evidence from the TRI-GUARD-PCI Registry (M. Bossard, Nov. 1, 11 a.m. PST, station 4)
• TCT 467: Site-Level Analysis of Infarct Size Reduction with LV Unloading in the STEMI-Door to Unload Trial (N. Mangner, Nov. 1, 3 p.m. PST, station 9)
• TCT 391: HRPCI in Heart Failure: The Impact of Left Ventricular Unloading on Cost Effectiveness: A Markov Model. (M. Kodencherry, Nov. 1, 2:50 p.m. PST | Station 6)
• TCT 888: Peri-procedural and Early Post-Procedural Mortality Following HRPCI (V. Panoulas, Nov. 2, 1 p.m. PST, station 2)
• TCT 1228: Clinical Characteristics and Early Mortality in a High-Risk PCI Cohort Similar to CHIP-BCIS3 Undergoing Impella Support: Insights from PROTECT III. (V. Panoulas, MD, Nov. 3, 8:50 a.m. PST, station 10)

This work builds on a long-term commitment to evidence generation that has helped inform clinical practice and the evolution of care guidelines. Through ongoing and planned studies-including PROTECT IV RCT and other research across ischemic heart disease, heart failure, cardiac surgery and cardiogenic shock-Johnson & Johnson MedTech continues to partner with investigators and clinicians to advance the field and improve care for patients.

About Impella Heart Pumps

Impella heart pumps are temporary mechanical circulatory support devices designed to unload the heart and provide hemodynamic support. Impella technology is used in appropriately selected patients with severe coronary artery disease or cardiogenic shock, consistent with applicable indications and labeling.

Cardiovascular Solutions from Johnson & Johnson MedTech

Across Johnson & Johnson, we are tackling the world's most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary and peripheral artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more information about heart recovery, visit https://www.heartrecovery.com/en-us.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in surgery, orthopaedics, vision, and cardiovascular solutions at https://www.jnjmedtech.com/. Follow us at @jjmt_heartrecov and on LinkedIn.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to Impella heart pumps and the company's research and innovation programs. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from expectations and projections. Risks and uncertainties include challenges inherent in research and development; uncertainty of clinical success and regulatory approvals; commercial success; manufacturing difficulties and delays; competition; intellectual property challenges; product efficacy or safety concerns; regulatory actions; changes in customer behavior and spending; changes in laws and regulations; and trends toward healthcare cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.